Pancreatic Endocrine Tumors Pathology

Molecular Pathogenesis

• MEN-1 inactivation: Loss of chromosome 11q13 (MEN-1 gene encoding menin) represents the most common genetic alteration; menin acts as a chromatin regulator and tumor suppressor controlling cell proliferation and apoptosis
• mTOR pathway activation: Dysregulation of mammalian target of rapamycin signaling promotes cellular growth independent of growth factor stimulation
• DAXX/ATRX mutations: Alterations in chromatin remodeling genes occur in ~40% of non-functional PNETs and correlate with increased tumor grade
• TP53 and RB inactivation: Associated with higher-grade tumors and malignant behavior

Hormone-Specific Pathophysiology

• Insulinoma (β-cell origin): Autonomous insulin secretion independent of glucose concentration → unregulated hypoglycemia with inappropriate hyperinsulinemia; positive feedback loop perpetuates glucose utilization and prevents hepatic gluconeogenesis

• Gastrinoma (non-β-cell/delta-cell origin): Excessive gastrin production → sustained gastric acid hypersecretion → severe peptic ulcer disease, severe reflux, and diarrhea (from acid inactivation of pancreatic lipase); 70% arise in the "gastrinoma triangle" (bounded by junction of cystic and common bile ducts, junction of pancreatic neck and body, and junction of pancreas and duodenum)

• VIPoma (non-β-cell origin): Vasoactive intestinal peptide causes profuse watery diarrhea through increased intestinal cAMP → secretory diarrhea, hypokalemia, and hypochlorhydria (VIP inhibits gastric acid secretion)

• Glucagonoma (α-cell origin): Excessive glucagon → hyperglycemia, lipolysis-induced hypertriglyceridemia, and characteristic necrolytic migratory erythema (dermatitis from amino acid depletion and altered protein metabolism)

• Somatostatinoma (delta-cell origin): Somatostatin inhibits gastric acid, pancreatic enzyme secretion, and nutrient absorption → achlorhydria, steatorrhea, weight loss, and hyperglycemia (from inhibition of insulin secretion)

• Non-functional PNETs: Produce peptides lacking clinical hormonal effects or present with nonspecific symptoms; mass effect dominates clinical presentation

• MEN-1 syndrome (40% of PNETs): Autosomal dominant condition with menin gene mutations; pancreatic involvement nearly universal; typically multiple, smaller lesions with earlier presentation (fourth-fifth decade)

• Sporadic PNETs (60% of cases): No identifiable hereditary syndrome; typically present later (fifth-sixth decade); more likely to be solitary

• VHL syndrome, NF-1, TSC: Predispose to neuroendocrine tumor development through loss of tumor suppressor function

• Chronic hypergastrinemia: H. pylori infection, atrophic gastritis, and immunoproliferative small intestinal disease (IPSID) increase gastrin-producing cell hyperplasia risk

Insulinoma (Most Common Functional Tumor, ~70% of functional PNETs)

• Whipple's triad: (1) Symptoms of hypoglycemia (tremor, palpitations, sweating, confusion, seizures, loss of consciousness); (2) documented blood glucose <55 mg/dL during symptoms; (3) relief of symptoms with glucose administration
• Typically presents with fasting hypoglycemia or nocturnal symptoms
• Weight gain is characteristic (from frequent feeding to prevent hypoglycemia)
• Lab correlate: Inappropriately elevated insulin and C-peptide levels during documented hypoglycemia (insulin >3 mIU/L and C-peptide >0.2 nmol/L when glucose <40 mg/dL)

Gastrinoma (Second Most Common, ~20% of functional PNETs)

• Zollinger-Ellison Syndrome (ZES): Severe, refractory peptic ulcer disease often in unusual locations (distal duodenum, proximal jejunum)
• Intractable diarrhea (in 30% of patients, may be sole presenting symptom)
• Severe reflux esophagitis with potential stricture formation
• Fasting serum gastrin >1000 pg/mL is virtually diagnostic; also markedly elevated gastric acid output (>15 mEq/hour)
• Paradoxically, low gastric pH (<2) with elevated gastrin (distinguishes ZES from achlorhydria-related gastrin elevation)
• 70% are malignant and 60% are extrapancreatic (duodenal wall origin)

VIPoma (~10% of functional PNETs)

• "Pancreatic cholera" syndrome: Severe watery diarrhea (often >3 L/day), hypokalemia, hypochlorhydria, and dehydration
• Weight loss and fatigue from electrolyte derangement
• Abdominal cramping and flushing
• Serum VIP >75 pg/mL with secretory diarrhea (low osmotic gap)

Glucagonoma (~3% of functional PNETs)

• Classic triad: Hyperglycemia (often resistant to insulin), necrolytic migratory erythema, weight loss
• Necrolytic migratory erythema: Distinctive dermatitis with erythematous, scaly patches on lower abdomen, buttocks, and perineum; recurrent with crusting and erosion
• Pathogenesis: Amino acid deficiency and hyperglucagonemia impair wound healing and epithelial integrity
• Thromboembolism (from increased platelet aggregation)
• Anemia and hypoalbuminemia

Somatostatinoma (~2% of functional PNETs)

• Often clinically silent due to inhibitory nature of hormone; frequently discovered as incidental finding
• Steatorrhea and weight loss (impaired pancreatic enzyme secretion)
• Hyperglycemia and diarrhea
• Often large and metastatic at diagnosis

Non-functional PNETs

• Nonspecific constitutional symptoms: Weight loss, fatigue, abdominal pain
• Symptoms predominantly from mass effect: Abdominal mass, early satiety, obstructive jaundice (from pancreatic head location)
• Often advanced disease at presentation with metastases to liver and regional lymph nodes
• No specific hormonal syndrome despite peptide hormone production

Histological Findings

• Morphology: Uniform, polygonal to spindle cells with salt-and-pepper chromatin pattern (finely dispersed nuclear chromatin) and round nuclei; organized in nests and trabecular arrangements separated by delicate fibrovascular stroma

• Immunohistochemistry (IHC):
• Synaptophysin and chromogranin A: Universal markers of neuroendocrine differentiation (positive in >95% of tumors)
• Specific hormone stains: Insulin (β-cell), gastrin (G-cell), VIP, glucagon (α-cell), somatostatin (δ-cell) stain cytoplasm of corresponding tumor cells
• Functional tumors show IHC concordance with hormone product (positive staining)
• Non-functional PNETs: May be negative for specific hormones or show immunoreactivity without clinical syndrome

• Proliferation index:
• Ki-67 staining quantifies proliferation: Low (<3%), intermediate (3-20%), high (>20%)
• Directly correlates with tumor grade and malignant behavior
• WHO classification: Grade 1 (Ki-67 <3%, mitotic rate <2/10 HPF), Grade 2 (Ki-67 3-20%, mitotic rate 2-20/10 HPF), Grade 3 (Ki-67 >20%, mitotic rate >20/10 HPF)

Gross Pathology

• Size: Highly variable from <1 cm to >10 cm; functional tumors often smaller at presentation due to earlier symptomatic detection; non-functional tumors typically larger (>2 cm)
• Color: Tan, yellow, or reddish-brown with possible areas of hemorrhage and necrosis
• Cut surface: Homogeneous, soft; larger tumors may show degenerative changes
• Location: Insulinomas distributed throughout pancreas; gastrinomas favor duodenum and gastrinoma triangle; non-functional PNETs show no predilection

Biochemical Testing (Hormone-Specific)

• Insulinoma: Fasting glucose <55 mg/dL with detectable insulin (>3 mIU/L) and C-peptide (>0.2 nmol/L); 72-hour supervised fast is gold standard (induce hypoglycemia and confirm inappropriate hormone elevation)

• Gastrinoma: Fasting serum gastrin >1000 pg/mL (>10-fold upper normal) or gastric pH <2 with gastrin >200 pg/mL; secretin stimulation test (gastrin elevation >200 pg/mL above baseline favors ZES); gastric acid output >15 mEq/hour

• VIPoma: Fasting VIP >75 pg/mL with secretory diarrhea (stool osmolality <250 mOsm/kg, sodium <40 mEq/L); normal gastric pH distinguishes from gastrinoma

• Glucagonoma: Fasting glucagon >150 pg/mL (>10-fold upper normal) with hyperglycemia

• Somatostatinoma: Fasting somatostatin >160 pg/mL

Imaging

• CT/MRI: Detect tumor location and metastatic disease; functional tumors often enhance on arterial phase due to rich vascularity
• Endoscopic ultrasound (EUS): Superior sensitivity for small tumors (<2-3 cm), particularly for gastrinomas in duodenal wall; allows tissue sampling
• Somatostatin receptor scintigraphy (SRS): Highly sensitive for neuroendocrine tumors expressing somatostatin receptors; detects metastatic disease
• 68Ga-DOTATATE PET/CT: Superior sensitivity to SRS; increasingly used for staging

Diagnostic Criteria Summary

Insulinoma

• First-line: Surgical resection (curative in benign tumors); >90% are solitary and benign, allowing for simple enucleation or formal resection
• Preoperative localization critical (EUS, CT, MRI, intraoperative ultrasound)
• Medical management (diazoxide, somatostatin analogs) for inoperable or metastatic disease
• Diazoxide inhibits insulin secretion; somatostatin analogs suppress growth hormone-dependent effects

• Second-line medical therapy:
• Frequent small meals or continuous glucose infusions
• Diazoxide (200-400 mg/day) for symptomatic control
• Somatostatin analogs (octreotide) in select cases
• mTOR inhibitors (everolimus) for advanced disease

Gastrinoma (Zollinger-Ellison Syndrome)

• First-line medical therapy: High-dose proton pump inhibitors (PPI) as primary treatment for acid hypersecretion (omeprazole 60-120 mg/day or higher)
• PPIs are so effective that surgery timing has changed; medical management now preferred initial approach
• Surgical resection considered after initial medical stabilization for localized, resectable tumors

• Surgical resection:
• Attempted in resectable, non-metastatic gastrinomas
• Exploratory surgery mandatory because 60% are extrapancreatic (duodenal wall) and may be missed on imaging
• Even intra-operative endoscopy employed to identify small duodenal tumors
• Consideration of formal distal gastrectomy no longer routinely performed (PPI therapy adequate)

• Metastatic gastrinoma:
• PPI therapy for acid control
• Chemotherapy (streptozocin-based regimens) for progressive disease
• Somatostatin analogs, everolimus for symptomatic control
• Liver-directed therapies for hepatic metastases

VIPoma

• First-line medical therapy: Somatostatin analogs (octreotide 100-500 mcg/day SC or long-acting IM formulations)
• Often dramatically effective; controls diarrhea in >80% of patients
• Allows electrolyte normalization prior to surgery

• Surgery: Resection of primary tumor when feasible; however, 50-70% are malignant with metastases at diagnosis

• Advanced disease: Chemotherapy, mTOR inhibitors

Glucagonoma

• First-line: Surgical resection if resectable; often diagnosed late with metastatic disease

• Supportive care: Amino acid supplementation, treatment of dermatitis (zinc, somatostatin analogs)

• Chemotherapy: For unresectable or metastatic disease; somatostatin analogs for symptom control

Somatostatinoma

• Surgical resection when possible
• Often advanced at diagnosis; multimodal therapy with chemotherapy and somatostatin analogs

Non-functional PNETs

• Surgical resection:
• Primary treatment for localized tumors (stages I-III)
• Formal pancreatic resection (distal pancreatectomy, pancreaticoduodenectomy, enucleation based on location and size)
• Extended lymph node dissection recommended

• Monitoring for small tumors (<2 cm, non-metastatic): Surveillance with imaging every 3-6 months may be considered in MEN-1 patients where surgery risks may outweigh benefits

• Advanced/metastatic disease:
• Cytoreductive surgery for debulking in selected patients
• Systemic chemotherapy: Temozolomide + capecitabine (first-line); streptozocin-based regimens
• Somatostatin analogs: Lanreotide (CLARINET trial showed progression-free survival benefit)
• mTOR inhibitors: Everolimus (RADIANT-3 trial showed PFS benefit)
• Targeted radiotherapy: 90Y- or 177Lu-DOTATATE for somatostatin receptor-expressing tumors
• Liver-directed therapies: Hepatic resection, ablation, or embolization for isolated liver metastases

General Management Principles

• Imaging surveillance: CT or MRI every

Disease-related — emergencies

• Neuroglycopenic crisis (insulinoma): sustained autonomous insulin secretion blocks hepatic glucose output; signaled by seizure, focal deficit, or coma with documented glucose <55 mg/dL. Medical emergency — IV dextrose, then confirmatory testing per the Endocrine Society hypoglycemic disorders guideline. Repeated episodes can cause permanent cognitive impairment.
• Ulcer perforation or hemorrhage (Zollinger-Ellison): unopposed acid load overwhelms mucosal defense; signaled by free air, peritonitis, hematemesis, or melena. Emergency. Abrupt PPI withdrawal (including perioperatively, when the oral route is lost) causes rebound acid hypersecretion and re-ulceration — IV PPI must bridge the gap.
• Hypokalemia and hypovolemic shock (VIPoma): cAMP-driven secretory losses >3 L/day; signaled by flattened T waves, U waves, arrhythmia, and metabolic acidosis from bicarbonate loss. Emergency — aggressive fluid/potassium repletion precedes any operation.
• Venous thromboembolism (glucagonoma): hypercoagulability with a striking rate of DVT/PE; sudden dyspnea or pleuritic pain warrants imaging. Emergency.

Disease-related — non-urgent

• Hepatic metastasis and progression: the dominant cause of death; rising chromogranin A or new DOTATATE-avid lesions signal it. Higher Ki-67 (WHO grading) predicts it.
• Obstructive jaundice/duodenal obstruction: mass effect from non-functional head lesions.

Treatment-related

• Somatostatin analogs: inhibition of gallbladder motility and enzyme secretion → cholelithiasis, steatorrhea, and hyperglycemia.
• Diazoxide: KATP channel opening plus renal sodium retention → edema, hyperuricemia, hypertrichosis.
• Chronic high-dose PPI: impaired B12 and magnesium absorption → macrocytosis, tetany.
• Pancreatic resection: postoperative pancreatic fistula (amylase-rich drain output), endocrine and exocrine insufficiency; distal pancreatectomy with splenectomy mandates post-splenectomy vaccination.
• Systemic therapy: everolimus → stomatitis, pneumonitis, hyperglycemia; streptozocin → nephrotoxicity; 177Lu-DOTATATE (per NCCN) → renal and marrow toxicity.

• "Salt-and-pepper" chromatin: the histologic buzzword for any neuroendocrine tumor; confirm with synaptophysin and chromogranin A, then grade with Ki-67 (WHO). Amyloid deposits in the stroma point specifically to insulinoma (IAPP/amylin).
• Whipple triad → 72-hour supervised fast is the single best next step for suspected insulinoma, per the Endocrine Society hypoglycemic disorders guideline. Do not order imaging first — biochemical proof precedes localization.
• C-peptide is the discriminator: high insulin with high C-peptide = insulinoma or sulfonylurea; high insulin with suppressed C-peptide = exogenous insulin (factitious). The commonest distractor is surreptitious sulfonylurea use — a negative oral hypoglycemic agent screen is required before calling it insulinoma.
• Elevated gastrin is not automatically gastrinoma: PPI therapy and atrophic gastritis/pernicious anemia are far more common causes. The distinguishing feature is gastric pH <2 with hypergastrinemia; achlorhydria points away from ZES. PPIs should be withheld before gastrin testing, and a secretin stimulation test producing a paradoxical rise in gastrin confirms the diagnosis.
• MEN1 = the 3 P's (parathyroid, pituitary, pancreas), autosomal dominant, menin at 11q13. Examiners test the sequencing: per the Endocrine Society MEN1 guideline, treat primary hyperparathyroidism first — normalizing calcium lowers gastrin and improves ZES control. Multiple, multicentric duodenal gastrinomas are the rule in MEN1.
• Gastrinoma triangle anatomy and the fact that most gastrinomas are duodenal, not pancreatic, explain why exploration plus intraoperative duodenal inspection is needed when imaging is negative.
• Somatostatinoma triad — diabetes, gallstones, steatorrhea; duodenal/ampullary somatostatinomas with psammoma bodies are the classic NF-1 association.
• 68Ga-DOTATATE PET/CT is the highest-yield functional imaging modality (NCCN); it outperforms older octreotide scintigraphy and also identifies candidates for peptide receptor radionuclide therapy.